| Name | Title | Contact Details |
|---|---|---|
Dan O'Neill |
Vice President of Information Technology | Profile |
Jeff Hrkach |
Senior Vice President of Technology Development | Profile |
At Target RWE, we are redefining and revolutionizing the generation and delivery of real-world evidence. Contact us today!
Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases.
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.
There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.